Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Axcan, QLT PhotoTherapeutics Inc. deal

AXP will acquire exclusive worldwide rights, except Japan, to QLTI's Photofrin photodynamic

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE